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After the age of 40, the amount of growth hormone in humans decreases. The reduced activity of the GH-IGF axis may play a role
in age-related cognitive impairments. In the present study, mood and cognition of 30 healthy subjects (7 males, 23 females, aged
41–76 yr, mean age 60.9 ± 9.0) were examined twice. At baseline, we determined fasting blood levels of GH and IGF-I. Mood
and cognitive status were assessed at baseline and after, on the average, 3 years and 9 months of followup. Working memory
performance decreased over the years in the low IGF-group (P = .007), but not the high IGF-I group. Higher levels of GH were
related with a better working memory at the second test (r = 0.42, P = .01) while higher levels of IGF-I tended to be related with
a better working memory (r = 0.3, P = .06). The results suggest that higher serum levels of GH and IGF-I preserve the quality of
working memory functions over the years.
1. Introduction
Growth hormone (GH) is secreted from the pituitary gland
and stimulates the liver to produce insulin-like growth factor
I (IGF-I). After the age of 40 the amount of growth hormone
in humans progressively decreases and an increasing age-
associated cognitive impairment is seen, as compared to
subjects aged between 20 and 30 yrs [1, 2]. As IGF-I levels
have been found associated with mood as well as cognitive
functioning, the reduced circulating IGF-I levels may play
a role in age-related psychological impairments. With respect
to mood, adults with growth hormone deficiency (GHD),
a pathological state characterized by low IGF-I levels, feel
less energetic, are emotionally more labile and experience
feelings of social isolation at a significantly higher frequency
than controls [3]. With respect to cognitive functions, IGF-
I plasma levels of healthy elderly were positively associated
with mini mental state examination (MMSE) scores [4].
Similarly, IGF-I levels in elderly healthy men were found to
be associated with better performance in tests sensitive to the
eﬀects of aging, especially fluid intelligence [5] and verbal
fluency and MMSE [6]. With respect to age-related cognitive
impairments, higher serum total IGF-I levels in healthy
subjects above 55 years were associated with less cognitive
decline over the following two years. The Mini-Mental
State Examination (MMSE) was used to assess cognitive
impairment at baseline and cognitive decline after, on the
average, 1.9 year of follow-up [7]. In two studies separate in
males and females, cognitive functions of subjects of 65 years
and older were related to levels of free IGF-I and IGF-I to
IGFBP-3 molar ratio determined from stored blood samples.
Cognitive functions were assessed by means of telephone-
based tests. Levels of free IGF-I measured in blood samples
collected at a mean age of 57 years in men were positively
related to global and verbal memory performance on average
of 18 years later, and IGF-I levels collected at a mean age of 56
years in women to general cognition on average of 10 years
later. These results indicate that higher midlife free IGF-I
may be associated with better late-life cognition [8, 9]. Quite
recently, low IGF-I levels were found to be associated with
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cognitive decline in hypertensive elderly subjects aged 65 year
and older [10] and with a prolonged latency of the P300
event-related potential, which may predict cognitive decline,
in males aged between 30 and 50 years [11].
Increasing knowledge is present on the mechanisms
underlying the relationship between the GH-IGF-I axis and
brain function. For instance, there is evidence that GH can
cross the blood-brain barrier [12], and binding sites for GH
and IGF-I are found in the brain in the choroid plexus, hypo-
thalamus, putamen, thalamus, and hippocampus [13, 14]. In
these brain areas, which play a role inmood andmemory, the
number of GH receptors declines with aging [15]. In addi-
tion, IGF-I potentiates acetylcholine release from the hip-
pocampus, and aging is associated with a dramatic reduction
of IGF-I protein levels and receptor density in this structure
[16, 17].
IGF-I has important functions in the development and
diﬀerentiation of the central nervous system [18]. Growth
and development of neurons in the dentate gyrus of the hip-
pocampus are modulated by IGF-I. With aging reductions
in IGF levels and in neurogenesis are shown. For instance,
plasma concentrations of IGF-I, IGF-II and IGFBP3 were
found to be reduced in subjects aged 65 to 92 years presenting
no malnutrition and no inflammation as compared to
healthy controls aged 20 to 65 years [19].
As IGF-I levels fall with aging and correlate with cognitive
decline, the possible role of IGF-I levels in the development
of dementia has been examined. For instance, the relation-
ship between the hypothalamus-pituitary-adrenal function,
IGF-I and IGF-binding proteins (IGFBPs) was studied in
patients with Alzheimer’s disease (AD). Patients with AD had
lowered IGF-I and IGFBP-3 levels and higher IGFBP-1 levels
compared to controls [20]. IGF-I levels correlated inversely
with cognitive impairment. In another study in 49 healthy
centenarians (mean age 100.4 year), cognitive functioning
was assessed by clinical dementia rating. Centenarians with
lower IGF-I levels had higher prevalence of dementia [21].
In a previous study we explored the stimulatory eﬀect of
a nutritional supplement on the GH-IGF-I axis and cogni-
tion in healthy subjects (aged 40 to 76). SerumGH, IGF-I and
cognitive function were assessed at baseline and again after
three weeks. Disregarding the eﬀects of treatment, we found
that a higher increase in IGF-I across sessions was related to
more improvement in working memory and vigor [22].
The objective of the present study was to evaluate
whether the GH-IGF-I status determined approximately 4
years earlier in middle-aged and elderly healthy subjects is
predictive for their later mood state and/or cognitive fun-
ctioning. We administered a parallel version of the psycho-
logical tests used almost 4 years earlier to the same subjects
to evaluate the relationship between previously determined
GH/ IGF-I levels and later test performance. We hypothe-
sized that higher IGF-I and/or GH levels are associated with
better psychological functions determined four years later.
2. Materials and Methods
2.1. Subjects. A number of 30 apparently healthy subjects (7
males, 23 females, aged 41 to 76 years, mean age 60.9 ± 9.0)
participated in this study. They previously participated in a
study on the eﬀect of a nutritional food supplement on GH
and IGF-I plasma levels and cognitive function [22]. The
total group of subjects participating in the original study
consisted of 42 healthy nonobese volunteers, 14 males and 28
females, aged 40 to 76 years. At baseline, blood was collected
for the measurement of serum GH and IGF-I levels. At the
end of 2005, all participants received a written invitation
to take part in a follow-up study, consisting of a parallel
version of the psychological tests. From these 42 subjects,
30 responded and underwent a second test administration,
separated by about 4 years from the first study. Mean
baseline values of the participating subjects were for GH
6.7 nmol/L (SD = 13.2) and for IGF-I 18.2 nmol/L (SD = 6.0).
Excluded at baseline were subjects with professional sports
participation, vegetarians, alcohol consumers (>3 units/day),
dieters, subjects addicted to substance abuse, subjects who
used, within 1 month prior to start of the study, hypnotics,
antidepressants, or nutritional supplements. The study was
conducted according to the Declaration of Helsinki and was
approved by the Ethics Committee of the VU University
Medical Center. All subjects gave their written informed
consent before inclusion in the study. The baseline data
collection of this study took place January–February 2002
and the second data collection in October–November 2005.
2.2. Tests and Procedure. Subjects were examined individu-
ally in a quiet room. The sequence of the tests was the same
for all subjects, and the test procedure as a whole took about
45 minutes.
A parallel version of the tests used in the previous study
[22], and selected from the Neurobehavioral Evaluation
System (NES) [23], was administered by means of a personal
computer.
2.2.1. Mood
The Profile of Mood States (POMS). It is a self-administered
questionnaire in which the subjects rate themselves with
respect to their feelings over the previous 3 days. The
shortened Dutch version of 32 items was used, which consists
of five subscales: depression, anger, fatigue, vigor, tension and
a total mood score (average of all subscales). In the present
study, we evaluated fatigue, vigor and total mood. Responses
are made by choosing from five response alternatives. Score:
The rating (1–5) on each item and the scale to which each
item contributes is recorded. With respect to Vigor a higher
score corresponds to a better mood state. For the other scales
a higher score points to a worse mood state.
2.2.2. Short-Term Memory and Intermediate Memory
Associate Learning Task. Nine word pairs consisting of
a name and an occupation were displayed on a computer
screen at a constant rate of one pair per 3 seconds. After
these pairs were presented, the subject was asked to choose
one of the nine occupation alternatives. After each answer,
the results were given in the following manner: “Yes, John
is a grocer,” or “No, Susan is a teacher.” Three trials were
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given in which the subject has to learn as many paired names
and occupations as possible. By means of this recognition
procedure short-term verbal learning is measured. Score: the
total of correct associations (maximum score: 27).
Visual Digit Span Task. A sequence of digits was presented
one at a time to the subject. After the whole sequence was
presented, the subject was required to enter the sequence
on the computer keyboard. Increasingly longer spans of
digits were presented, until the subject made two errors at
a span length. Score the length of the longest span answered
correctly (maximum score: 9).
Associative Learning Delayed Recognition Task. To assess
intermediate recall, a single recognition trial of the nine
names to be matched with one of the nine occupations used
in the associate learning test was administered at the end of
the testing session. Score: the number of correct responses
(maximum score: 9).
2.2.3. Working Memory (WM)
Digit Span Backward. In the second part of the visual digit
span task the subject was asked to respond with the order
of digits reversed (backward), measuring working memory
performance. Score: the length of the longest span answered
correctly (maximum score 8).
WM Composite. We assessed prefrontal functions by calcu-
lating a working memory score composed by adding the
score on the first trial of the associate learning task and
the score on the digit span backwards task. As these two
tasks require the most active manipulation of the material
to be remembered a summation of the scores represents a
score for working memory capacity. Score: the sum of correct
responses of the first trial of the associate learning task and
the score on the digit span backwards (maximum score: 17).
2.3. Baseline Hormone Assays. Blood samples were taken
once, that is at baseline a 5-cc venous blood sample was
drawn after an overnight fast for determination of serumGH
and IGF-I levels. The blood samples were centrifuged (10
minutes, 3500 r.p.m. at 4◦C) and serum was stored at −20◦C
until analysis.
Serum GH and IGF-I levels were measured using com-
mercially available assays (GH, immunometric assay, Sorin
Biomedica, Saluggia Italy; IGF-I, Chemoluminiscentic, Nich-
ols Institute Diagnostics, San Juan Capristrano, USA). The
detection limits for GH and IGF-I are 1.0mU/L (0.5 μg/L)
and 0.6 nmol/L, respectively. The intra-assay coeﬃcient of
variation (CV) for GH is 4% at serum GH of 4mU/L. The
interassay coeﬃcient of variation for GH is 9% at serum GH
of 2.5mU/L and 8% at serum GH of 8.6mU/L. For IGF-I
the intra-assay coeﬃcient of variation is 3% at serum IGF-
I of 20 nmol/L and the inter assay coeﬃcient of variation is
6% at serum IGF-I of 33 nmol/L and 8% at serum IGF-I of
7 nmol/L.
2.4. Data Analysis. Data were analysed by means of ANOVA
with groups (low/high GH/IGF-I) as independent factor and
session as repeated measurements factor (original baseline
and present study). Subjects with GH values above the
median GH (median GH = 2.25 nmol/L) were assigned to
the high GH group (n = 15) and those with values below
the median to the low GH group (n = 15). Similarly,
a distinction was made between a group with IGF-I values
above (n = 15) and a group with values below the
median (n = 15; median IGF-I = 17.5 nmol/L). In case an
interaction was found between group and session, paired t-
tests (one-tailed) were performed. In addition, we calculated
the bivariate Pearson correlation coeﬃcient between GH and
IGF-I levels and the partial correlation coeﬃcient between
GH/IGF-I values and test scores at the second session
controlling for the baseline test scores.
Significance level was defined as P ≤ .05. Tests were
one tailed, based on the assumption that higher GH/IGF-
I values would be associated with better test scores at the
second session relative to baseline. Data were analysed using
the SPSS version 14 software package (SPSS Inc., Chicago,
USA).
3. Results
The serum GH and IGF-I levels of 30 subjects out of the
original group of 42 subjects could be related to scores on
the psychological tests. Baseline data were similar for the 30
volunteers and 12 nonparticipating subjects, except for GH
level, nonparticipating subjects having lower GH (but not
IGF-I) levels (P = .03).
With regard to the GH-IGF-I axis, the Pearson correla-
tion between GH and IGF-I values was significant (r = 0.43,
P = .009). With respect to the GH groups, the mean GH
value in the low group was 0.8mU/L (SD = 0.6) and in the
high group 12.5mU/L (SD = 16.9). In addition, the mean
IGF-I value in the low IGF-I group was 13.8 nmol/L (SD =
2.8) and in the high IGF-I group 22.5 nmol/L (SD = 5.05).
ANOVA indicated a significant main eﬀect for session for
digit span backward (baseline, mean = 5.2, SD = 1.7; session
2, mean = 4.47, SD = 1.3; F (1, 28) = 8.5, P = .007, η2 =
0.23) and WM composite (Baseline, mean = 9.23, SD = 2.5;
session 2, mean = 8.17, SD = 2.27; F (1,28) = 4.8, P = .037,
η2 = 0.15. This means that working memory performance
was decreased in the total group of subjects during the 4-
year interval. Mean values of mood and memory scores are
presented in Table 1.
With respect to the POMS, an interaction between GH
or IGF-I group and session was not found, indicating no
diﬀerential eﬀect of GH/IGF-I group on mood parameters.
Regarding the memory tests, there was no interaction
between GH group and session. However, a tendency for
an interaction between IGF-I group and session was found
for digit span backwards and WM composite (F (1,28) =
3.4, P = .07, η2 = 0.11, and F (1,28) = 3.2, P = .086,
η2 = 0.1, resp.). Paired t-tests indicated a significant decrease
in digit span backward and WM composite in the low IGF-
I group (t(14) = 2.08, P = .007, and t(14) = 2.6, P = .02,
resp.) whereas no significant eﬀect was found in the high
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Table 1: Mean mood and memory performance scores (±SD) for the low (n = 15; mean IGF-I = 13.8 nmol/L) and high (n = 15; mean
IGF-I = 22.5 nmol/L) IGF-I groups. Higher scores for fatigue, mood total, and symbol-digit correspond to worse performance. Higher scores
for the other tests correspond to better performance.
Low IGF-I High IGF-I
Baseline Session 2 Baseline Session 2
Vigor 3.25 ± 0.8 3.48 ± 0.7 3.39 ± 0.91 3.23 ± 1.21
Fatigue 2.73 ± 0.65 2.52 ± 0.7 2.84 ± 0.95 2.77 ± 1.21
Mood total 1.51 ± 0.31 1.55 ± 0.3 1.64 ± 0.41 1.64 ± 0.62
Associate learning trial 1 4.33 ± 2.09 3.6 ± 1.96 3.37 ± 1.7 3.80 ± 2.21
Associate learning trial 2 5.0 ± 1.81 4.67 ± 2.44 4.8 ± 1.97 4.53 ± 2.1
Associate learning trial 3 6.2 ± 2.18 6.13 ± 1.64 5.2 ± 2.30 5.4 ± 1.80
Associate recall 6.4 ± 2.2 5.6 ± 2.77 5.13 ± 2.10 5.47 ± 2.39
Digit span forward 6.13 ± 1.64 6.0 ± 1.0 6.0 ± 1.56 5.53 ± 1.64
Digit span backward 5.47 ± 1.55 4.27 ± 1.22 4.93 ± 1.83 4.67 ± 1.44
Symbol-digit (error) 2.47 ± 5.54 1.6 ± 2.67 3.36 ± 4.74 1.45 ± 1.69
WM composite 9.8 ± 2.48 7.87 ± 2.10 8.67 ± 3.13 8.47 ± 2.47
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Figure 1: Mean scores (±SE) on digit span backward at baseline
and session 2 for the low (n = 15; mean IGF-I = 13.8 nmol/L) and
high (n = 15; mean IGF-I = 22.5 nmol/L) IGF-I groups.
IGF-I group. This result indicates that working memory
performance in the low IGF-group decreased across the years
while the working memory in the high IGF-I group was not
significantly decreased relative to baseline (Figure 1).
In addition to the ANOVA with repeated measurements,
we calculated the partial correlation coeﬃcient between the
baseline values of at one hand GH and IGF-I and on the
other hand the psychological test scores at the second test
session. The baseline test scores were controlled for. There
were no significant correlations between GH or IGF-I with
mood state parameters. However, GH correlated significantly
with the scores on the first trial of associate learning (r =
0.39, P = .02) while IGF-I values tended to correlate with
the scores on this test (r = 0.25, P = .09). With respect to
WM composite, GH significantly correlated with these scores
(r = 0.42, P = .01) and IGF-I tended to correlate (r = 0.3,
P = .06) suggesting that higher GH and IGF-I values are
related with a better working memory at the second test
session.
4. Discussion
In the present study, we examined whether higher con-
centrations of GH and/or IGF-I levels in healthy adults
above 40 years are indicative of their psychological functions
about 4 years later. Contrary to our previously observed
associations between IGF-I levels and mood parameters in
healthy subjects [22], we found no association between IGF-
I concentration and mood status. The results of the analyses
of variance indicate that the concentration of IGF-I was
related to memory performance determined 4 years later.
The group with higher IGF-I levels showed a relatively better
memory performance at the second test session. In contrast,
no diﬀerences between the low and high GH groups were
seen with respect to psychological test scores. The corre-
lation analyses indicated significant associations between
GH values and memory and a trend towards significant
associations between IGF-I values and memory. As GH levels
were only determined in one daily sample, it was surprising
to observe significant associations between GH and memory
parameters. A single determination of the GH concentration
is assumed not to be very reliable because GH is secreted
in a pulsatile fashion, with 2/3 of the daily secretion taking
place at night. However, although in the present study
the correlation coeﬃcient between concentrations of GH
and IGF-I levels was not very substantial, the levels were
significantly associated. Thus, a single determination of GH
may yet be reliable enough to reveal relationships between
the GH/IGF-I axis and psychological parameters. Indeed,
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it has been shown that, because of homeostatic control
mechanisms within the GH-IGF-I axis, the day to day mean
mass of GH secretion per burst and the serial orderliness
of the GH release in healthy persons is strongly preserved
across a wide span of ages and body-compositions [24]. For
instance, the intraindividual mean mass of GH secretion
per burst has been found to be highly conserved across
sessions (r = 0.93) and consecutive days (r = 0.92) in
healthy men (age range, 29–77 yr) from whom every 10min
blood samples were drawn during 48 hours. As we did not
observe diﬀerences between the high and low GH groups
on psychological parameters but yet found that GH and
cognitive functions were correlated, it may well be true that
the interindividual and intraindividual variability in GH
levels results in a higher sensitivity to observe associations
between the GH/IGF-axis and memory functions than is
the case for IGF-I. Thus, the more stable IGF-I marker
for GH status may be more appropriate for discerning
cognitive diﬀerences between IGF-I groups, but less sensitive
for detecting interindividual associations between GH/IGF-I
axis and cognitive parameters.
The present results indicate that there is a relationship
between GH and IGF-I levels and cognitive performance
in healthy adults across the years. Higher levels of GH and
IGF-I seem to be related to a better memory performance
in the consecutive years. Regrettably, because of practical
constraints, we were not able to take blood samples for
determination of serum GH and IGF-I at the second test
session. It may thus well be true that intermediating factors
account for the observed relationship between GH/IGF-
I and memory. One such factor may be lifestyle. For
example, food or sport habits associated with the original
baseline GH and IGF-I serum levels may explain the better
memory performance at the second test session. Although
professional sports participants and users of nutritional
supplements were excluded at baseline, it cannot be excluded
that subjects diﬀered with respect to healthy life style habits.
A healthier life style may improve mental functions directly
or indirectly by increasing GH/IGF-I levels.
The results of the present study suggest a relation
between the GH/IGF-I axis and working memory. The
digit span backward task used in the present study may be
assumed to be quite powerful, because remembering in the
reverse order increases task load substantially. Indeed, the
high and low IGF-I groups were distinguishable on this task,
the high IGF-I group performing better. Thus, especially
the performance on a working memory task with high task
load may diﬀerentiate groups. The eﬀects of the GH/IGF
axis on memory may be attributed to neurophysiological
mechanisms associated with the regenerative action of IGF-
I, but also GH, in the adult CNS or be due to an increase
of locally produced IGF-I within the brain [25]. Specifi-
cally, these underlying mechanisms may be related to the
presence of IGF-I receptors in the frontal cortex and to
neuroprotective eﬀects of IGF-I with respect to cholinergic
neurons in the forebrain [26]. In addition, as is stated in
the Introduction, IGF potentiates acetylcholine release from
the hippocampus and modulates growth and development
of neurons in the dentate gyrus of the hippocampus [16–18].
The involvement of the GH/IGF-I axis in the activity of the
hippocampus and prefrontal cortex is associated with the
N-methyl-D-aspartate (NMDA) receptor. GH substitution
in GH-deficient patients has been found to increase CSF
levels of aspartate [12], an excitatory amino acid which is
a ligand for the N-methyl-D-aspartate (NMDA) receptor.
Activation of the NMDA receptor contributes to long-term
potentiation of synaptic eﬃcacy in the hippocampus, which
is considered to be an inherent mechanism of memory
consolidation in the mammalian brain [27]. Moreover, it has
been shown that activation of NMDA receptors in the basal
forebrain modifies attentional functions [28].
A former fMRI study showed that GH-deficient patients
had a higher than normal activity in parietal cortex and pre-
frontal cortex during the performance of a working memory
task, whichmay be due to compensatory recruitment of these
brain regions [29]. These findings indicate that the GH/IGF-
I axis contributes to prefrontal functioning and may thus
mediate and preserve memory functions.
Overall, we conclude that circulating GH, and IGF-I
levels may influence cognitive functions, higher serum levels
of GH and IGF-I preserving the quality of working memory
functions over the years.
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